IPO | Ophthalmology Innovation Source

The Ophthalmology Market – A View Of The Public Sector & Exit Trends

Jeffrey Hoffman, Managing Director and Head of West Coast Healthcare Investment Banking for J.P. Morgan, told attendees at the Ophthalmology Innovation Summit in Chicago how ophthalmology companies are helping to drive up the biotechnology sector. Presenter: Jeff Hoffman Jeff Hoffman is a Senior Managing Director at Guggenheim Securities, LLC. He has more than 25 years…

Ocular Therapeutix Starting to Sprint

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 016″] Prior to starting Ocular Therapeutix, Amar Sawhney, already a successful medtech entrepreneur, was a bit concerned about the unique challenges posed by the ophthalmology sector. Today, with the commercial launch of its ReSure Sealant underway and a successful IPO completed, Sawhney says he’s more than confident in the plan to…

Ophthalmology Leaders Speak to Strength of Sector

A Wall Street Journal analysis of venture capital commitments showed ophthalmology remained the strongest sector within healthcare. According to the Wall Street Journal, privately held ophthalmology start-ups drew $442.7 million in capital over the first six months of this year, putting it on pace to surpass the $848.9 million raised in 2013. With the baby…

Innovation Cycle Overview & Financing Environment Update

Presenter: William J. Link, PhD Bill was Founder, Chairman and CEO of Chiron Vision, sold in 1997. Bill founded and served as President of American Medical Optics (AMO), sold in 1986. View Full Profile

EU Commercialization Strategies

Summit Co-Chair and Managing Director for InterWest Partners, Gilbert Kliman MD, captures the audience’s thoughts on commercialization strategies in Europe through a series of live polling questions. Also gaining the expert opinions of panelists, Laurent Attias, David Muller, David E.I. Pyott, Jim Mazzo and Andy Corley, Gil compares the who, what and where questions that…

Bill Link Dives into his Perspective of Venture Overseas

William J. Link PhD, Managing Director for Versant Ventures, gives the audience at the 5th Annual Ophthalmology Innovation Summit a look into the returns on the venture investing side and the comparison between the US and Europe. Utilizing specific data and numbers, Bill continues to share his personal biases as an American in the US…

The Ophthalmology Market – “A View from the Public Sector”

Jeffrey Hoffman, Managing Director and Head of West Coast Healthcare Investment Banking for JPMorgan, gladly addresses the audience at the 5th Annual Ophthalmology Innovation Summit with a promising outlook. Expanding on the rise of individual company risks, Jeffrey shares specific increases in the biotech and life sciences markets, as they recover from a 10-year lull.…

Going Public – Who, When, and Why?

Detailing the grueling process and levels of determination necessary to go public, David Guyer, CEO for Ophthotech, begins this panel discussion with some of the more trying aspects of going public. Continuing to lead this distinguished panel through a IPO focused conversation, David stresses the importance of timing and perseverance throughout the planning and on…

Aerie Advances to the Next Round in Glaucoma Treatment

Vicente Anido Jr. PhD, Chairman & CEO for Aerie Pharmaceuticals, provides the attendees of the 5th Annual Ophthalmology Innovation Summit with an overview of Aeries rapid changes throughout the past year. Aerie focuses on the treatment of Glaucoma and has two major products, AR-1324 and Latanapross. Having just completed their initial Public Offering, Aerie can…

Funding Ophthalmic Innovation

Angela MacFarlane, President & CEO for ForSight Labs and Emmett Cunningham, Partner for Clarus Ventures co-moderate a segment on funding opportunities for innovative products and procedures in the Ophthalmic space, at the 2nd Annual Ophthalmology Innovation Summit on April 18, 2013. Lending their expert insights on the funding process are panelists Calvin W. Roberts, MD,…